602 related articles for article (PubMed ID: 27401477)
1. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.
Yaguchi T; Kawakami Y
Int Immunol; 2016 Aug; 28(8):393-9. PubMed ID: 27401477
[TBL] [Abstract][Full Text] [Related]
2. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
5. Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.
Kouidhi S; Ben Ayed F; Benammar Elgaaied A
Front Immunol; 2018; 9():353. PubMed ID: 29527212
[TBL] [Abstract][Full Text] [Related]
6. New insight into cancer immunotherapy.
Escribese MM; Barber D
Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():50-55. PubMed ID: 29108766
[TBL] [Abstract][Full Text] [Related]
7. Active Immunotherapy of Cancer.
Chodon T; Koya RC; Odunsi K
Immunol Invest; 2015; 44(8):817-36. PubMed ID: 26575466
[TBL] [Abstract][Full Text] [Related]
8. Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
[TBL] [Abstract][Full Text] [Related]
9. Introduction to checkpoint inhibitors and cancer immunotherapy.
Sharpe AH
Immunol Rev; 2017 Mar; 276(1):5-8. PubMed ID: 28258698
[No Abstract] [Full Text] [Related]
10. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.
Overwijk WW
Curr Opin Immunol; 2017 Aug; 47():103-109. PubMed ID: 28806603
[TBL] [Abstract][Full Text] [Related]
11. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
12. Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.
Kean LS; Turka LA; Blazar BR
Immunol Rev; 2017 Mar; 276(1):192-212. PubMed ID: 28258702
[TBL] [Abstract][Full Text] [Related]
13. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.
Dammeijer F; Lau SP; van Eijck CHJ; van der Burg SH; Aerts JGJV
Cytokine Growth Factor Rev; 2017 Aug; 36():5-15. PubMed ID: 28693973
[TBL] [Abstract][Full Text] [Related]
14. Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
Lucca LE; Hafler DA
Immunol Rev; 2017 Mar; 276(1):9-25. PubMed ID: 28258696
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.
Xie Y; Xiang Y; Sheng J; Zhang D; Yao X; Yang Y; Zhang X
J Immunol Res; 2018; 2018():8740976. PubMed ID: 29785403
[TBL] [Abstract][Full Text] [Related]
16. Novel immunotherapies for hematologic malignancies.
Nelson MH; Paulos CM
Immunol Rev; 2015 Jan; 263(1):90-105. PubMed ID: 25510273
[TBL] [Abstract][Full Text] [Related]
17. Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists.
Emerson DA; Redmond WL
BioDrugs; 2018 Jun; 32(3):221-231. PubMed ID: 29637478
[TBL] [Abstract][Full Text] [Related]
18. TIGIT: A Key Inhibitor of the Cancer Immunity Cycle.
Manieri NA; Chiang EY; Grogan JL
Trends Immunol; 2017 Jan; 38(1):20-28. PubMed ID: 27793572
[TBL] [Abstract][Full Text] [Related]
19. Strategies for combining immunotherapy with radiation for anticancer therapy.
Seyedin SN; Schoenhals JE; Lee DA; Cortez MA; Wang X; Niknam S; Tang C; Hong DS; Naing A; Sharma P; Allison JP; Chang JY; Gomez DR; Heymach JV; Komaki RU; Cooper LJ; Welsh JW
Immunotherapy; 2015; 7(9):967-980. PubMed ID: 26310908
[TBL] [Abstract][Full Text] [Related]
20. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
